Voyager Therapeutics (VYGR) reported new data from its two preclinical programs targeting tau for the treatment of Alzheimer’s disease. Data on ...
Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical muri ...
For example, all statements Voyager makes regarding Voyager’s ability to advance its AAV-based gene therapy programs and tau antibody program, including expectations for Voyager’s achievement ...
March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported new data from its ...
a scientist from the Voyager program. "Every bit of additional data we have gathered since then is not only valuable bonus science for heliophysics, but also a testament to the exemplary ...
Voyager Therapeutics has a 52 week low of $ ... The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline ...
Interesting Engineering on MSN6d
NASA’s Webb telescope captures Neptune’s auroras in stunning detail for first timeNASA’s James Webb Space Telescope used its Near-Infrared Spectrograph to capture Neptune’s auroras in stunning detail.
Long-Sought Auroral Glow Finally Emerges Under Webb’s Powerful Gaze Neptune lies in the cold, dark reaches of the outer edges ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback